Objective: Capecitabine, a prodrug of 5-fluorouracil, is currently used in the treatment of metastatic colorectal and breast cancers. The aim of this study was to review the pharmacological mechanisms, treatment strategies, and documented case reports of capecitabine-induced hand-foot syndrome (HFS). Methods: All case reports documented in the PubMed, Web of Science, and Scopus databases up to February 2018 were searched and reviewed using the keywords capecitabine, hand-foot syndrome, and case report. Results: The database search identified 373 articles in the literature; of these, 88 articles (having 111 case reports) in the English or Turkish language having a full-text access were included in the study. The median duration of capecitabine-induced HFS was 28 (range, 7-140) days, and the daily dose of capecitabine ranged between 850 and 5000 mg/m2 in cases wherein capecitabine was applied as monotherapy(n=19). A dose reduction or treatment discontinuation, systemic or topical treatment alone or in combination, and the use of henna, vitamin E, or pyridoxine were preferred options in the treatment of HFS. Conclusion: Health care providers and patients should be aware of developing capecitabine-induced HFS and its risk factors. Early recognition and treatment initiation for HFS are important to maintain effective chemotherapy in patients with cancer.
INTRODUCTION
Capecitabine is used as an adjuvant treatment in colorectal cancer; as the first-line treatment in metastatic colorectal, gastric, pancreatic, and head and neck cancers; and as monotherapy or in combination with docetaxel in metastatic breast cancer (1) . Although capecitabine is well tolerated by patients, hand-foot syndrome (HFS) is one of the common adverse events, which causes a significant degree of morbidity (2, 3) . HFS was first described by Zuehlke in 1974 as an erythematous/malignant rash on the hands and toes of patients who received mitotane (4) .
The incidence of capecitabine-induced HFS is approximately 50%-60%, and the severe (≥grade 3) form of HFS occurs in approximately 10%-70% of cases. The syndrome is dosedependent, and its occurrence is associated with the peak drug concentration and the total cumulative doses of capecitabine (5) . HFS, also known as palmar-plantar erythrodysesthesia (PPE), chemotherapy-associated acral erythema, toxic palmar-plantar erythema, or Burgdorf reaction, is one of the most frequent adverse events of cytotoxic chemotherapy (6) . Although many cytotoxic drugs have been reported to cause HFS, it is more frequently observed in cases treated with 5-fluorouracil, liposomal doxorubicin, and cytarabine (7) .
After the first-pass metabolism of capecitabine in the liver as a prodrug, it is transformed into an active form (known as 5-fluorouracil) by thymidine phosphorylase in tumor cells, which inhibits the thymidylate synthesis in purine synthesis and blocks DNA replication and its repairing process ( Figure 1 ) (8) . The most frequently seen adverse event of capecitabine is based on dermis, which leads to vascular degeneration of keratinocytes, apoptosis, perivascular lymphocytic filtration, and edema (9) . HFS manifests as dysesthesia, palmar-plantar formication, and erythema at first, and its severity increases to a painful syndrome unless treated appropriately (4, 7) .
The National Cancer Institute graded the hand -and footrelated adverse effects as mild (Grade 1), moderate (Grade 2), severe (Grade 3), and life-threatening (Grade 4). Minimal skin changes, erythema, and peeling (Grade 1); moderate skin changes, swelling, and edema (Grade 2); painful erythema and swelling in the palms and soles (Grade 3); or pain with bloating, deep peeling, and ulceration (Grade 4) can be observed in various degrees in patients (10) .
The World Health Organization has classified HFS according to the symptoms, clinical appearance, and pathology. Dysesthesia and paranesthesia are accompanied by tingling in the hands and feet in Grade 1; swelling without pain in the hands and feet is observed and uncomfortable erythema occurs during walking and holding objects in Grade 2; painful erythema and swelling are observed in the palms and soles in Grade 3; and a significant increase in the severity of pain with bloating, deep peeling, and ulceration is observed in Grade 4 (10) . Patient self-monitoring tools have been developed for the self-evaluation of HFS symptoms by patients (11) (12) (13) (14) .
The mechanism of capecitabine-induced HFS has not been identified in detail; however, many hypotheses have been suggested ( Figure 1 ).
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Another hypothesis suggests that HFS occurs because of palmarplantar cyclooxygenase (COX) inflammatory-type reaction. COX-1 is found in almost all tissues and plays an important role in the protection of the gastric mucosa. COX-2 is normally found at low levels in the cells and is induced by inflammation and mutagenic stimulation; it plays a vital role in the synthesis of prostanoids (prostaglandin, prostacyclin, thromboxane, and eicosanoids) associated with pain and inflammation (16) .
Moreover, it is assumed that the carrier systems affect the absorption of capecitabine. The carriers within the membrane transport system, particularly skin membrane transport system, play a crucial role in the occurrence of capecitabine-associated toxicity along with the metabolism pathways. The ATP-binding cassette (ABC) carrier family is one of the membrane transport systems comprising proteins that transfer miscellaneous drugs, xenobiotics, and endogenous compounds from the membrane. These carrier systems eliminate antineoplastic drugs from tumor cells and prevent drug accumulation in the tumor tissue, thus leading to chemotherapy failure. Many ABC carriers play an important role in the fluoropyrimide-based chemotherapeutic response by determining the drug concentration within the cell that leads to cutaneous reactions on hands and feet (17).
METHODS
All case reports published in English or Turkish language up to February 2018 in the Pubmed, Scopus and Web of Science databases were searched by using the keywords of 'capecitabine', 'hand-foot syndrome' and 'case report'. A total of 373 articles were identified, and of these, 75 were found in the PubMed, 252 in the Scopus, and 46 in the Web of Science databases. Case reports having full-text access and providing information regarding the following criteria were included: cancer type, patient's age and sex, dose and duration of capecitabine, and treatment options for HFS. This study is a systematic review of published case reports. Therefore, a consent form was not necessary and an ethics committee approval was not sought for the study. However, the study was conducted and written according to the principles of Helsinki Declaration. The Statistical Package for Social Science version 23 (IBM, New York, United States) program was used for statistical data analysis in the study. The patients' demographics were obtained from the case reports, and data were summarized using descriptive statistics.
RESULTS
Of the 373 identified articles ( Figure 2 ), 285 were excluded due to duplicates in databases (n=90), not having fulltext access (n=18), not published in the English or Turkish language (n=48), and not relevant to the scope of the study (n=129). Therefore, 88 articles (having 111 case reports) were included in this study. Although there were variations in the characteristics of diseases, patients, dose, and duration of chemotherapy and preferred treatment for HFS in the reported cases, information regarding the cases was summarized based on the cancer type, patient's age, patient's sex, antineoplastic treatment, capecitabine dose, HFS occurrence during the capecitabine treatment (days), and treatment options for HFS in the study ( Table 1 ). 
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The author(s) declare that they have no conflict of ınterest, have no affiliations with or financial interests in any company, product, or described in the manuscript. Capecitabine-induced HFS occurred between 7 and 240 days of capecitabine monotherapy (n=62 cases). Among the cases receiving capecitabine monotherapy, the median (range) duration for the occurrence of capecitabine-induced HFS (n=24 cases) was 28 (7-140) days, and the daily dose of capecitabine (n=19 cases) ranged between 850 and 5000 mg/m2.
The combination of treatment strategies (n=34; 30.63%: systemic treatment ± topical treatment ± dose reduction ± treatment discontinued), capecitabine dose reduction (n=15; 13.51%), capecitabine discontinuation (n=15; 13.51%), the use of henna (n=11; 9.90%), the use of topical treatment (n=6; 5.40%), the use of vitamin E (n=4; 3.60%), and the use of pyridoxine treatment (n=2; 1.80) were observed in 111 cases. There was no information about the HFS treatment in 18 cases. Furthermore, the use of antibiotic therapy (n=1) and capecitabine replacement with other chemotherapeutic (n=1 cases) were seen, and no intervention was implemented in 3 cases.
The risk factors of developing HFS were previously indicated as advanced age, female sex, performance status, continuous chemotherapy infusion, a history of fluorinated pyrimidine administration, exposure to total body irradiation, preexisting diabetes, peripheral arterial disease and/or peripheral neuropathy, the use of tyrosine kinase inhibitors, hemoglobin level < 12 mg/dl, white blood cell counts, and the number of organs affected (106) (107) (108) (109) (110) .
The HFS manifestations can be seen in various degrees representing differences in the occurrence of scars and time to healing. A loss of fingerprints associated with HFS has recently been reported in a male patient with metastatic nasopharyngeal carcinoma treated with capecitabine for >3 years (10) .
There were no effective strategies established for the prevention or HFS treatment since the underlying mechanism is not fully elucidated in the literature. Therefore, dose reduction or cessation or postponing of therapy can be considered, particularly in patients with Grade 2 symptoms (111) . The Grade 2 symptoms may rapidly progress, and symptom relief may require longer time when it reaches Grade 3. This situation can lead to the cessation of chemotherapy; therefore, an early detection of Grade 2 symptoms is crucial for dose adjustment ( The treatment options for HFS were not used or were not indicated in 20 case reports included in the study. Many treatment strategies were investigated to alleviate and treat HFS symptoms including the use of antiperspirants, topical urea-lactic acid mixture, or vitamin E (113) (114) . Pyridoxine was used to relieve paresthesia and reduce the syndrome severity (106); however, studies showed that the use of pyridoxine as prophylaxis is not as effective as it was considered (115) (116) . The use of softening/ moisturizing creams as a prophylactic or therapeutic option was recommended for all grades of HFS, particularly Grade 1 (117) , which may prevent or delay dose reduction during the treatment. COX-2 inhibitors (6) and topical or systemic use of corticosteroids were shown to be effective in the prophylaxis and treatment of HFS; however, the effectiveness of steroids in capecitabine-induced HFS has not been proven yet (118) (119) due to the risk of skin thinning and aggravation of symptoms caused by the long-term use (117) . Immersing hands and feet in cold water and avoiding skin irritants and changes in temperature and/or pressure are examples of non-pharmacological treatment strategies (120).
DISCUSSION
Many case reports on capecitabine-induced HFS have been documented in the literature. The first case report on capecitabine-related HFS was published in 2003, and the number of cases has increased recently (22) . The summary of product characteristics included information about capecitabine-induced HFS. However, there is no specific information on the occurrence and treatment of HFS (1). The case reports included in the study had diverse information regarding patient's sex, age, medical history, performance status, and dose and duration of capecitabine treatment.
Therefore, it was difficult to identify particular risk factors for developing HFS.
Female sex is recognized as a risk factor for developing HFS. In this systematic review, 67 (60%) of the 111 cases were women, emphasizing the importance of this risk factor.
It was difficult to identify any correlation between the total and/or exposed cumulative dose of capecitabine and the first occurrence of HFS during treatment since there was no detailed information regarding the capecitabine dose and duration of treatment in these cases. In addition, patients' weight, previous chemotherapy cycles, and other confounding factors could not be extracted from the case reports to conclude this finding.
It was identified that capecitabine-induced HFS occurred between 7 and 240 days of the treatment. Among the treatment strategies used for HFS, pyridoxine, vitamin E, emollient creams, and henna were likely to be effective in alleviating the symptoms. However, the effective dose and duration of these treatments have not been established (113) (114) (115) (116) .
HFS is not a life-threatening complication, but it significantly reduces the patient's quality of life. When HFS does occur, certain problems with compliance may arise, and cessation of chemotherapy may be required. Therefore, early recognition of HFS is important for maintaining the patient's quality of life and continuity of treatment. Patient self-monitoring tools have been developed for assessing HFS symptoms, which can contribute to an active patient involvement in the chemotherapy process (11) (12) (13) (14) .
CONCLUSION
Capecitabine-induced HFS is a cutaneous skin reaction that affects the palms and/or soles of hands and is frequently observed with the use of cytotoxic drugs, particularly 5-flourouracil, capecitabine, liposomal doxorubicin, and cytarabine.
Considering the published studies, it is difficult to indicate the best treatment options for capecitabine-induced HFS since different strategies have been used for its management. Therefore, additional data from further clinical trials and/or meta-analysis are required to establish the most appropriate treatment strategy for HFS in different patient populations.
It is essential that patients should be informed about the early signs and symptoms of HFS, and they be closely monitored by health care providers for early diagnosis and appropriate management of HFS.
In conclusion, health care providers and patients should be aware of developing capecitabine-induced HFS, its associated risk factors, and early initiation of treatment options during chemotherapy.
